Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Stopped The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.
Conditions
- Metastatic Leiomyosarcoma
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Advanced Myxoid Liposarcoma
- Advanced Soft Tissue Sarcoma
- Metastatic Myxoid Liposarcoma
- Metastatic Round Cell Liposarcoma
- Metastatic Soft Tissue Sarcoma
- Refractory Leiomyosarcoma
- Refractory Myxoid Liposarcoma
- Refractory Round Cell Liposarcoma
- Refractory Soft Tissue Sarcoma
- Refractory Synovial Sarcoma
- Refractory Undifferentiated Pleomorphic Sarcoma
- Advanced Leiomyosarcoma
- Advanced Synovial Sarcoma
- Advanced Undifferentiated Pleomorphic Sarcoma
- Metastatic Chondrosarcoma
Interventions
- DRUG: Itacitinib
- OTHER: Laboratory Biomarker Analysis
Sponsor
Fred Hutchinson Cancer Center
Collaborators